Drugs that contain Asciminib Hydrochloride

1. List of Scemblix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(10 years from now)

US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

NCE-1 date: October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic